FDA clears DxNow ’ s sperm separation device

Medical device developer DxNow said today it won FDA 510(k) clearance for its ZyMōt ICSI and ZyMōt multi sperm separation devices designed for use in assisted reproductive technology procedures. The newly cleared devices from the Gaithersburg, Md.-based company are designed for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection, intrauterine insemination and in vitro fertilization procedures. “We are excited to announce the achievement of this significant milestone in our company’s evolution. This announcement follows CE certification and the introduction of our sperm separation devices in Turkey and several European, Latin American and Asian countries. We have developed devices that make ART procedures faster and less demanding for reproductive medicine professionals. Equally important, we are offering a new pathway for enabling the selection of stronger and healthier sperm, with the ultimate goal of supporting infertile couples striving to conceive,” co-founder &CEO Bill Sharp said in a press release. DxNow said the devices are the first of their kind to win clearance and approval in the US. The systems are intended to simulate the cervical and uterine patheway to facilitate the separation and preparation of highly-motile sperm with normal morphology for use in ART procedures. “This is an outstanding validation of our core technology platforms. It is very gratifying to k...
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance dxnow Source Type: news

Related Links:

Abstract Non-obstructive azoospermia (NOA) is the most severe clinical diagnosis in cases of male infertility. Although in some cases of NOA spermatozoa can be retrieved by microdissection testicular sperm extraction (micro-TESE) to fertilise eggs through intracytoplasmic sperm injection (ICSI), there remains a lack of potential biomarkers for non-invasive diagnosis before micro-TESE surgery. To determine predictive biomarkers for successful sperm retrieval before micro-TESE, the aim of this study was to explore whether microRNAs (miRNAs) were differentially expressed in testicular tissues in NOA patients in whom ...
Source: Reproduction, Fertility, and Development - Category: Reproduction Medicine Authors: Tags: Reprod Fertil Dev Source Type: research
This article is protected by copyright. All rights reserved.
Source: Molecular Reproduction and Development - Category: Reproduction Medicine Authors: Tags: REVIEW ARTICLE Source Type: research
Condition:   Infertility Intervention:   Sponsor:   Aljazeera Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractChemotherapy-induced gonadal dysfunction resulting in transient or persistent infertility depends on the type of drugs and cumulative dose, and it is an important long-term complication, especially for adolescent and young adult (AYA) cancer patients. Due to its importance, a clinical practice guideline for fertility preservation in childhood and AYA cancer patients was published by the Japan Society of Clinical Oncology (JSCO) in 2017. Although the precise mechanisms remain unclear, several studies reported that the cancer itself, not the cancer treatment, adversely affected semen quality. It is reported that that...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Infertility Interventions:   Behavioral: Fasting;   Behavioral: No fasting Sponsor:   Kasr El Aini Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: ICSI (Intracytoplasmic Sperm Injection) | Infertility | Medical Devices | Middle East Health | Reproduction Medicine | Turkey Health | USA Health